Department of Bioengineering and Therapeutic Sciences

Michael Fischbach, PhD, who studies drug-like molecules produced by human gut bacteria, has been awarded one the 16 prestigious 2011 Packard Fellowships in Science and Engineering.

Pharmaceutical companies will increasingly apply the predictive modeling of quantitative pharmacology to do more efficient drug development, says Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department

Adam Abate, PhD, a faculty member in the UCSF Schools of Pharmacy and Medicine, Department of Bioengineering and Therapeutic Sciences, is a prime trial candidate for QB3’s Startup in a Box.

The new UCSF Center for Quantitative Pharmacology housed within the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department of the Schools of Pharmacy and Medicine, will be inaugurated next week with a wide-ranging, 2-day conference, September 22 and 23, 2011 at William J. ...

Louis R. Cantilena, Jr., MD, PhD, is the newly appointed course director of the American Course on Drug Development and Regulatory Sciences (ACDRS) effective summer 2011.

A novel gene associated with the asthma susceptibility in African Americans was revealed by a U.S. consortium of asthma genetics researchers, including Esteban G. Burchard, MD, MPH, Department of Bioengineering and Therapeutic Sciences,

Michael Williams, MA, is the first executive director of academic, administrative, and research technology for the UCSF School of Pharmacy, effective August 1, 2011.

Faculty awards: Cutler, Fujimori, Huang, Wells. New faculty members: Abate, VanOsdol, Rodondi. Retiring faculty members: Kahl, Shafer, Wang, Kayser, Koo. PharmD students: Campbell, Wheeler, Ho, Lam, Campbell, Loucks, Marotto, Huynh, Luu, Chua, Stephens. PhD students: Gray. New appointments: Penick...

The 2nd Annual Bay Area Biotechnology Symposium, presented by the UCSF School of Pharmacy’s Industry Outreach Program in coordination with the UCSF Postdoctoral Scholars Association at Mission Bay in late May 2011, fully lived up to its billing: “Pharmaceuticals of the Futur

Magnetic resonance imaging (MRI), used with a novel pyruvate chemical compound that is specially labeled to be read by the MRI machine, is being applied for the first time in humans to study the aggressiveness of prostate cancer in patients and the success of prostate cancer therapies.